I am a board-certified medical oncologist who specializes in caring for people with liver cancer, gallbladder cancer, bile duct cancer, pancreatic cancer, and other gastrointestinal cancers. My primary goal is to provide the best possible treatment and individualized care for people with these diseases. I work closely with a team of surgeons, radiation oncologists, and other medical professionals who specialize in the diagnosis and treatment of gastrointestinal cancer.
Read more Read less
In my research, I am trying to find new, effective therapies for gastrointestinal cancer, particularly primary liver and bile duct tumors. I am working on ways to use a patient’s own immune system to fight cancer, which is called immunotherapy. In addition, I am investigating strategies to block specific cellular pathways that cancer uses to grow.
I am also interested in improving how we conduct clinical research with patients and increasing access to clinical trials so we can help people with cancer receive new therapies closer to home. I am a standing member of the Institutional Review Board, the committee that approves all clinical research at Memorial Sloan Kettering.
My research and training has been supported by the American Society of Clinical Oncology, the National Comprehensive Cancer Network, the National Institutes of Health, the American Association for Cancer Research, and the Howard Hughes Medical Institute. In collaboration with basic scientists, my work has been published in the New England Journal of Medicine, Nature Medicine, the Journal of Clinical Oncology, Cancer Discovery, and Cancer.
- Clinical Expertise: Gastrointestinal Malignancies; Hepatobiliary Cancers; Pancreatic Cancer; Early Drug Development; Immunotherapy
- Languages Spoken: English
- Education: MD, Albert Einstein College of Medicine
- Residencies: Internal Medicine - NewYork-Presbyterian Hospital
- Fellowships: Oncology/Hematology - Memorial Sloan Kettering Cancer Center
- Board Certifications: Internal Medicine; Medical Oncology
Research is integral to our mission at Memorial Sloan Kettering, and clinical trials help us discover better forms of patient care and treatment. For you, this could mean access to a new therapy or therapy combination. Click to see a list of the trials I’m currently leading.
Read more Read less
Clinical Trials Led by James J. Harding
- A Phase I Study of ADI-PEG 20 plus FOLFOX in Patients with Advanced Digestive Cancers
- A Phase I Study of LY3321367 with or without LY3300054 Immunotherapy in Patients with Advanced Solid Tumors
- A Phase I Study of PF-06671008 Immunotherapy in Patients with Advanced Solid Tumors
- A Phase I/II Study of CX-2009 to Treat Patients with Inoperable or Metastatic Solid Tumors
- A Phase I/II Study of Enzalutamide with and without Sorafenib in Patients with Advanced Liver Cancer
- A Phase I/II Study of INCAGN01876 Immunotherapy in Patients with Advanced Solid Tumors
- A Study Assessing Nivolumab Immunotherapy Added to Chemoembolization for Liver Cancer
Clinical Trials Co-Investigated by James J. Harding
- A Phase I Study of AZD5363 in Patients with Solid Tumors Who Have AKT1 and PIK3CA Mutations
- A Phase II Study of Entrectinib in Patients with Locally Advanced or Metastatic Solid Tumors Containing Gene Rearrangements in NTRK1/2/3, ROS1, or ALK
- A Phase II Study of MEDI4736 and Tremelimumab, as Monotherapy or in Combination, in Unresectable Hepatocellular Carcinoma
Most major health insurers offer plans that include MSK as one of their in-network providers. If MSK is in-network, it means all our doctors are too. Medicaid and New York State Medicare also provide benefits for care at MSK.Learn more